GSK is “betting big on the US” and engaged in "constructive" talks on drug pricing with President Donald Trump’s administration, according to Emma Walmsley, the outgoing chief executive officer of the British drugmaker. Pfizer Inc.'s pricing deal with Trump is a “step forward and it’s progress,” Walmsley said at Bloomberg’s Women, Money & Power event in London. (Source: Bloomberg)
